NCT04870944 2026-02-24CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaChildren's Oncology GroupPhase 1/2 Recruiting63 enrolled
NCT04500548 2025-09-10Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyNational Cancer Institute (NCI)Phase 1 Withdrawn